In February 2025, the U.S. equity capital markets (ECM) saw 35 offerings raise $24.4B in total volume. Six IPOs contributed $2.8B, on average trading up 10.8% on the open on dollar-weighted basis. Notably, 83.3% of U.S. IPOs priced within or above the initial range.
SPAC IPO volumes remain steady, with 8 SPACs raising $1.7B. February marked the ninth consecutive month with at least 5 SPAC IPOs hitting the market.
Follow-on offerings dominated issuance, with 29 deals raising $21.9B. The average file-to-offer discount was 8.2%, compared to 5.5% in 2024 and 8.4% last month. Financial services accounted for 61.5% of follow-on volume (55.1% including IPOs), marking the sector’s highest monthly dollar volume since May 2020 and the third highest since 2010. Eight issuers priced their first follow-on offering, raising a combined $2.0B with an average-file-to offer discount of 14.8%. Additionally, 14 Emerging Growth Companies (EGCs) raised $2.9B, with only one month in the past year seeing less than $1.3B in EGC-related ECM volume.
Charles Schwab’s (SCHW) $13.1B marketed follow-on is the third largest issuance in the last 10 years and the largest clean-up trade. The deal outperformed the average Day-1 performance for follow-on offerings in February, trading up 5.0% compared to 2.1%. Sailpoint (SAIL) priced its IPO on February 12, marking the second IPO of 2025 to exceed $1B. This already represents 40% of the total amount seen in 2024, which had five such IPOs. SAIL opened flat but gained 11.7% by Day 3.
EMEA ECM saw 20 offerings totaling $14.6B, a 76.8% increase from February last year. Six IPOs raised $2.1B, with all pricing within their expected range. The combined ECM volume for January and February was the highest since at least 2019, marking a 25.0% increase over the next strongest start to a year ($16.3B in 2021).
Contact [email protected] to request a demo.
This information provided is for informational purposes only, and should not be construed as legal, tax, investment, financial, or other advice. You should not act or refrain from acting on the basis of any of this information. Past performance is no guarantee of future results. CMG shall have no liability whatsoever for your use of this information.